Shares of ImmunoCellular Therapeutics Ltd (NYSE: IMUC), engaged in developing immune-based therapies for the treatment of cancers, recorded over 18.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. IMUC was the top performer in the U.S. healthcare sector after skyrocketing 40.8% and closed at $1.00 Tuesday, while recording significant trading volumes of 4.7 million shares. IMUC breached its key technical resistance level of 50-Day DMA at $0.72. Recently, the company announced that the European Medicines Agency (EMA) has provided scientific advice supportive of advancing ICT-107 to a registrational phase III program in patients with newly diagnosed glioblastoma (GBM). During the past 5-trading sessions, IMUC gained 60.5% with daily average trading volumes of 1.4 million shares, while the stock accumulated 46.7% gain during the past one month with daily average trading volumes of 604,952 shares. The stock is up 8.1% year-to-date.
Company Description:
ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) is a development stage company that seeks to develop imaging devices with medical diagnostic applications.
1-Year Stock Chart:
Source: Bloomberg
